Clinicopathological study of malignant melanoma in a regional cancer center

Panda, Sasmita; Dash, Sashibhusan; Besra, Kusumbati; Samantaray, Sagarika; Pathy, Pramod Chandra; Rout, Niranjan

doi:10.4103/ijc.ijc_612_17

Cited by 26 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, ophthalmic melanoma was reported as the most common in a study from a leading ophthalmology referral center. In other study, albeit with small numbers, anorectal and extremity were the predominant sites (43% for both) (25). Among various histopathological subtypes, nodular melanoma was the most common in our study.…”

Section: Discussionsupporting

confidence: 46%

Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India

et al. 2021

View full text Add to dashboard Cite

BackgroundTreatment of malignant melanoma has undergone a paradigm shift with the advent of immune checkpoint inhibitors (ICI) and targeted therapies. However, access to ICI is limited in low-middle income countries (LMICs).Patients and MethodsHistologically confirmed malignant melanoma cases registered from 2013 to 2019 were analysed for pattern of care, safety, and efficacy of systemic therapies (ST).ResultsThere were 659 patients with a median age of 53 (range 44–63) years; 58.9% were males; 55.2% were mucosal melanomas. Most common primary sites were extremities (36.6%) and anorectum (31.4%). Nearly 10.8% of the metastatic cohort were BRAF mutated. Among 368 non-metastatic patients (172 prior treated, 185 de novo, and 11 unresectable), with a median follow-up of 26 months (0–83 months), median EFS and OS were 29.5 (95% CI: 22–40) and 33.3 (95% CI: 29.5–41.2) months, respectively. In the metastatic cohort, with a median follow up of 24 (0–85) months, the median EFS for BSC was 3.1 (95% CI 1.9–4.8) months versus 3.98 (95% CI 3.2–4.7) months with any ST (HR: 0.69, 95% CI: 0.52–0.92; P = 0.011). The median OS was 3.9 (95% CI 3.3–6.4) months for BSC alone versus 12.0 (95% CI 10.5–15.1) months in any ST (HR: 0.38, 95% CI: 0.28–0.50; P < 0.001). The disease control rate was 51.55%. Commonest grade 3–4 toxicity was anemia with chemotherapy (9.5%) and ICI (8.8%). In multivariate analysis, any ST received had a better prognostic impact in the metastatic cohort.ConclusionsLarge real-world data reflects the treatment patterns adopted in LMIC for melanomas and poor access to expensive, standard of care therapies. Other systemic therapies provide meaningful clinical benefit and are worth exploring especially when the standard therapies are challenging to administer.

show abstract

Section: Discussionsupporting

confidence: 46%

Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pigmented lesions contribute a significant number of lesions biopsied for various reasons, but of primary concern is 12 , "Chang et al" 13 and "Mukhopadhyay et al", 2 reported 82% and 78% of the cases to be of cutaneous origin. During our study period, there were no non cutaneous melanomas.…”

Section: Discussionmentioning

confidence: 99%

A histo-pathological study with an emphasis on stratification of pigmented lesions of the skin

Anand¹,

Ilanthodi²,

N³

et al. 2020

IJPO

View full text Add to dashboard Cite

Pigmented lesions can be close mimickers of melanoma and clinically challenging to diagnose. These can be melanocytic or non-melanocytic pigmented disorders. Pigmented lesions are close mimickers of melanoma and histopathology is a cornerstone for diagnosing these lesions. 1.To study the histomorphological patterns of pigmented lesions of the skin; 2. To categorise and differentiate pigmented lesions from melanoma based on histomorphology.A total of 70 histologically diagnosed cases of pigmented lesions of the skin were retrospectively studied from January 2018 to December 2019 in department of Pathology, of a Tertiary care center, Mangalore (India). Clinically suspicious skin lesions were taken up for the study. Sections from the skin punch biopsies and wide excision of the lesion were processed, stained with Hematoxylin and Eosin stain and studied for its histomorphological features.Out of the 70 cases studied, 22 cases were melanocytic lesions including 12 cases of Malignant melanoma (17.1%), Benign Naevi- 10 cases (14.2%) and 48 cases were non-melanocytic lesions including Lichen planus- 30 cases (42%), Seborrheic keratosis- 10 cases (14.3%), Basal cell carcinoma- 8 cases (11.4%).The pigmented lesions are categorised into melanocytic and non melanocytic lesions for a better understanding. Among the Melanocytic lesions, our study witnessed predominantly cutaneous melanoma. And in non melanocytic lesions lichen planus predominated.

show abstract

“…Among these different types of melanoma, cutaneous melanoma is by far the most prevalent. For instance, the histopathological diagnosis of malignant melanoma in India during a period of 5 years showed that 93.4% of the cases were cutaneous melanoma, whereas only 6.6% non-cutaneous melanoma were characterized in conjunctiva, anorectum, gingiva-buccal sulcus, vagina, palate, and the nasal cavity [20]. Although cutaneous melanoma has a higher likelihood in Caucasians than in other ethnicities, mucosal melanoma incidence is not race dependent [21].…”

Section: Cutaneous and Non-cutaneous Melanomamentioning

confidence: 99%

RAGE Signaling in Melanoma Tumors

Olaoba

Kadasah

Vetter

et al. 2020

IJMS

View full text Add to dashboard Cite

Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.

show abstract

Clinicopathological study of malignant melanoma in a regional cancer center

Cited by 26 publications

References 25 publications

Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India

Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India

A histo-pathological study with an emphasis on stratification of pigmented lesions of the skin

RAGE Signaling in Melanoma Tumors

Contact Info

Product

Resources

About